Under this partnership, Alvotech Contract Services will be responsible for commercial production using its new state-of-the-art biosimilar facility in Reykjavik, Iceland, where the manufacturing process will be scaled up and process validation performed. Alvotech and Prestige Biopharma will immediately commence technology transfer, followed by commercial manufacturing of the compound.
“The partnership with Prestige BioPharma marks an important milestone for our company as we work towards expanding our contract manufacturing business,” said Mark Levick, chief executive officer, Alvotech. “We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”
Alvotech’s contract manufacturing services include: cell line, process, analytics development or transfer; scale-up and GMP manufacturing (multiple 2000L); aseptic DP filling: vials and PFS; process characterization, validation and commercial supply; and regulatory support.